On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors of Immunic, Inc. The resignation was not due to any disagreement with the company regarding its operations, policies, or practices. Consequently, the Board size was reduced from ten members to nine members. Immunic, Inc. operates in the biotechnology industry and develops immunotherapies for autoimmune diseases.

Immunic reported a net loss of $34.1 million ($0.80 per share) for the second quarter ended June 30, 2026, compared to a $26.8 million loss in the prior year period. Total operating expenses rose to $35.3 million from $27.1 million, driven by increased R&D and G&A costs. The company holds $155.1 million in cash and expects funding into late 2027. On August 6, 2026, the board appointed Elena Ridloff as a Class I director to strengthen financial expertise ahead of pivotal Phase 3 ENSURE trial data expected by year-end for its lead drug vidofludimus calcium in relapsing multiple sclerosis. Concurrently, Dr. Daniel Vitt resigned from the Board and terminated his employment with the Company Subsidiary under a separation agreement providing approximately $946,375 in severance payments plus a €15,000 monthly consulting retainer. Immunic is a late-stage biotechnology company pioneering novel oral therapies for neurologic diseases.

On June 29, 2026, Tamar Howson resigned from the Board of Directors and the Compensation Committee as she transitions into retirement. Following this, the Board appointed CEO Erik Lundgren to serve as a Class II director until the 2028 annual meeting of stockholders. Immunic, Inc. is a biotechnology company focused on developing immune-modulating therapies.

At its annual meeting on June 29, 2026, Immunic, Inc. stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan to increase authorized common stock by 6,000,000 shares, bringing the total to 8,644,887 shares. Shareholders also elected Michael Bonney, Thorvald Nagel, and Dr. Richard Rudick as Class III Directors to serve until the 2029 annual meeting. Additionally, the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Immunic, Inc. is a biotechnology company.